(Q39631908)

13 September 2017

title

PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study (English)

1 reference

13 September 2017

1

Steven A Kaplan

1 reference

13 September 2017

Mohamed A Ghafar

2

1 reference

13 September 2017

Michael A Volpe

3

1 reference

13 September 2017

John S Lam

4

1 reference

13 September 2017

Debra Fromer

5

1 reference

13 September 2017

Alexis E Te

6

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

13 September 2017

1 reference

13 September 2017

volume

60

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

464-468

1 reference

13 September 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Incidence and clinical significance of false-negative sextant prostate biopsies.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Androgen metabolism in men receiving finasteride before prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

The effect of finasteride on prostate specific antigen: review of available data

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Effect of finasteride on prostate-specific antigen density

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901760-0

7 January 2021

10.1016/S0090-4295(02)01760-0

Identifiers

DOI

1 reference

13 September 2017

1 reference